Free Trial

Erasca 11/12/2024 Earnings Report

Erasca logo
$1.89 +0.01 (+0.53%)
As of 01/31/2025 04:00 PM Eastern

Erasca EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Erasca Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Erasca Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

Erasca Earnings Headlines

Erasca: Future 'Streamlined' But Still Uncertain
Starting 2025 Strong: 2 AI Stocks Under $10 You Can’t Miss
As we step into 2025, artificial intelligence (AI) continues to revolutionize industries with groundbreaking advancements. From the surge in generative AI technologies transforming creative processes to AI-driven automation enhancing operational efficiencies, the landscape is brimming with innovation. These rapid developments are creating lucrative opportunities for investors who recognize the potential of emerging AI companies.
Bank of America Securities Reaffirms Their Buy Rating on Erasca (ERAS)
See More Erasca Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Erasca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Erasca and other key companies, straight to your email.

About Erasca

Erasca (NASDAQ:ERAS), a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

View Erasca Profile

More Earnings Resources from MarketBeat